Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3)

Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) is an RNA-binding protein characterized by two N-terminal RNA recognition motifs and four C-terminal KH domains essential for binding and regulating mRNA fate. Highly expressed in embryonic tissues and upregulated in a wide spectrum of cancers, IGF2BP3 promotes tumorigenesis through mRNA stabilization, translational activation, and protection of oncogenic transcripts (such as IGF2, MYC, EGFR) from degradation. Beyond its role in cancer, its ability to function as an m6A reader positions it centrally in epitranscriptomic regulation. Clinically, IGF2BP3 is established as a diagnostic and prognostic biomarker for numerous cancers, and experimental data highlight its potential as a therapeutic target, especially for drug-resistant and aggressive tumors.

Other names

IMP3KOC1VICKZ3Insulin-like growth factor II mRNA-binding protein 3

Targeting IGF2BP3 may reduce cancer cell proliferation, invasion, metastasis, and drug resistance by inhibiting mRNA stabilization and translation of oncogenic transcripts such as IGF2, MYC, and EGFR. Modulation of m6A reading activity may disrupt oncogene expression.